ACO/ARO/AIO-23
Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist Anakinra for rectal cancer patients. A phase II trial of the German Rectal Cancer Study Group
II
interventionell
National
Status: In Vorbereitung
Zeitraum
2025
2029
Zentren
10
Zentren gesucht
Patienten
90
19.03.2024
Klinische Settings
II
neoadjuvant
1st line
kurativ
Identifier
AIO-KRK-0224/ass
Kontakt
Leitung
Prof. Dr. med. Emmanouil Fokas
Ansprechpartner*in
Prof. Dr. med. Emmanouil Fokas
E-Mail emmanouil.fokas@uk-koeln.de